Triple-negative breast cancer (TNBC), accounting for 15–20% of breast cancers [2], does not benefit from endocrine therapy or classic targeted therapy due to the absence of estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor (HER-2) gene amplification. Here, PGR is linked to triple-negative breast carcinoma.